FDA Grants Rolling Review of Palvella’s QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations
Go back to FDA Grants Rolling Review of Palvella’s QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations| (NASDAQ: PVLA) | Delayed: 138.94 -4.27 (2.98%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $143.21 | 52 Week High | $ | |||
| Open | $144.45 | 52 Week Low | $ | |||
| Day High | $144.45 | P/E | N/A | |||
| Day Low | $136.68 | EPS | $ | |||
| Volume | 85,028 | |||||
